Read our June 2021 issue

We feature a combination of landscape articles and active partnering company profiles focused upon dealmaking, CNS diseases, ophthalmic diseases and infectious diseases, including vaccines.

Advertisement

  • This month we showcase the six-part Nature Careers podcast series, ‘Business of Science,’ which ran in May and June 2021 and aimed to teach new entrepreneurs about the first steps of research commercialization, from registering a patent, to scaling up and beyond.

    • Raveena Bhambra
    News Feature
  • Building on an evolutionary ruse to cross the physiological blood–brain barrier, NEUWAY Pharma’s engineered protein capsules (EnPC) are poised to usher in a new era of effective CNS therapies.

    • NEUWAY Pharma GmbH
    Advertisement Feature
  • Herantis is capitalising on the power of the natural protein Cerebral Dopamine Neurotrophic Factor (CDNF) to restore proteostasis and slow, stop, or even reverse neurodegeneration.

    • Herantis Pharma
    Advertisement Feature
  • With its unique mRNA therapeutics platform, Arcturus Therapeutics is a leading clinical-stage mRNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases.

    • Arcturus Therapeutics Holdings
    Advertisement Feature
  • Building on its history of successful collaborations, Sanofi Pasteur, the vaccines global business unit of Sanofi, is seeking partners with a common drive for excellence and pursuit of innovation.

    • Sanofi Pasteur
    Advertisement Feature
  • Avalon GloboCare, a leading biotechnology company focusing on cell-based technology and therapeutics, is using its leading technology platforms to begin clinical trials of its potential COVID-19 therapy, a mucosal intranasal spray vaccination against SARS-CoV-2, and is developing drugs to combat cancer metastasis.

    • Avalon GloboCare Corp.
    Advertisement Feature
Artificial intelligence in drug development

Artificial intelligence in drug development

From rapid candidate selection, to fewer clinical trials and faster market approval, artificial intelligence approaches are helping to accelerate and improve the efficiency of the drug development process, whilst significantly reducing costs. Here we present a number of companies working in the field.
Collection